Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease

BACKGROUND: High inter‐individual variability in therapeutic response to drugs used in the management of Inflammatory Bowel Disease (IBD) leads to high morbidity and high costs. Genetic variants predictive of thiopurine‐induced myelosuppression, thiopurine‐induced pancreatitis and immunogenicity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bangma, Amber, Voskuil, Michiel D., Uniken Venema, Werna T. C., Brugge, Harm, Hu, Shixian, Lanting, Pauline, Franke, Lude, Dijkstra, Gerard, Festen, Eleonora A. M., Weersma, Rinse K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Efficacy of a Pharmacogenetic Passport for Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318341/
https://www.ncbi.nlm.nih.gov/pubmed/32363635
http://dx.doi.org/10.1111/apt.15762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318341/
https://www.ncbi.nlm.nih.gov/pubmed/32363635
http://dx.doi.org/10.1111/apt.15762

Ejemplares similares